AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-64. Canceled

65. (Currently Amended) A compound of formula I,



I

wherein:

R^1 represents Het^1, $R^{1a}C(O)$- or D-A-N(H)-$[Q]_n$-C(O)-E-C(O)-;

R^{1a} represents:

H,

aryl ~~(which latter group is~~ optionally substituted by one or more substituents selected from the group consisting of OH, halo, cyano, nitro, $N(R^{3a})R^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy~~)~~,

aromatic or part-aromatic C_{13-14} tricyclic carbocyclyl ~~(which latter group is~~ optionally substituted by one or more substituents selected from the group consisting of OH, halo, cyano, nitro, $N(R^{3a})R^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy, and when the C_{13-14} tricyclic carbocyclyl is~~which latter group, if~~ part-aromatic, a non-aromatic part of the C_{13-14} tricyclic carbocyclyl is optionally substituted ~~in the non-aromatic part~~ by one or two oxo groups~~)~~ or

C_{1-12} alkyl ~~(which latter group is~~ optionally substituted and/or terminated by one or more substituents selected from the group consisting of halo and aryl, wherein the aryl ~~(which latter group~~ is optionally substituted by one or more substituents selected from the group consisting of OH, halo, cyano, nitro, $N(R^{3a})R^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy~~)~~;

A represents~~, at each occurrence when used herein,~~ C_{2-6} alkylene or A^1-C(O)N(H)-A^2, wherein A^2 is attached to ~~the group~~ D;

A^1 represents C_{1-4} alkylene;

A^2 represents C_{2-5} alkylene;

D represents~~, at each occurrence when used herein,~~ -N(R^{2a})R^{2b}, -C(=NR^{2c})N(R^{2d})R^{2e} or -N(R^{2f})C(=NR^{2g})N(H)R^{2h};

R^{2a} and R^{2b} independently represent H, C_{1-6} alkyl, or Het^2, or R^{2a} and R^{2b} together represent $(CH_2)_{3-6}$, wherein the $(CH_2)_{3-6}$~~which alkylene group~~ is optionally interrupted by NR^4 and/or is optionally substituted by one or more C_{1-4} alkyl groups;

R^4 represents H, C_{1-6} alkyl or Het^3;

R^{2c} to R^{2h} independently represent H or C_{1-6} alkyl;

E represents -E^1-Het^4-, E^{2a}, -$(CH_2)_{0-3}$N(H)C(O)-E^{2b}-C(O)N(H)$(CH_2)_{0-3}$- or is represented by~~a structural fragment of~~ the formula



~~wherein~~ E^3 represents $(CH_2)_{1-2}$, CH=CH, CH=N, CH_2-N(R^a), $(CH_2)_{0-1}$C(O), $(CH_2)_{0-1}$O or $(CH_2)_{0-1}$S;

R^a represents H or C_{1-6} alkyl;

E^1 represents $(CH_2)_{0-2}$ or CH=CH;

E^{2a} and E^{2b} independently represent C_{2-4} alkenylene, C_{3-6} cycloalkylene, phenylene or naphthylene;

Het^1 to Het^4 independently represent four- to twelve-membered heterocyclic groups containing one or more heteroatoms selected from N, O and S, which heterocyclic groups are optionally substituted by one or more substituents selected from

the group consisting of =O, OH, halo, cyano, nitro, $N(R^{3a})R^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy;

R^{3a} and R^{3b} independently represent~~, at each occurrence when used herein,~~ H or C_{1-4} alkyl, or R^{3a} represents $-C(O)R^5$;

R^5 represents H or C_{1-4} alkyl;

n represents~~, at each occurrence when used herein,~~ 2, 3, 4 or 5;

each individual Q independently represents a structure represented by~~structural fragment of~~ formula Ia, Ib, Ic, Id, Ie or If



Ia



Ib



Ic



Id



Ie



If

wherein

R^6 represents H or C_{1-6} alkyl;

R^7 represents C_{1-12} alkyl;

R^8, R^9, R^{10} and R^{11} independently represent H or C_{1-12} alkyl;

G represents CH or N;

L represents O or S; and

p, q and r independently represent 0, 1, 2 or 3; ~~and~~

provided that the compound comprises at least one ~~structural fragment of~~structure represented by formula Ib, Ic, Id, Ie or If in which R^6 or R^7, R^8, R^9, R^{10} or R^{11}, respectively, represents branched, cyclic or part cyclic C_{3-5} alkyl; or a pharmaceutically acceptable derivative thereof.

66. (Currently Amended) A compound as claimed in Claim 65, wherein:

R^{1a} represents H or C_{1-12} alkyl~~, which latter group is~~ optionally substituted and/or terminated by one or more substituents selected from halo and aryl~~, which latter group is~~ optionally substituted by one or more substituents selected from the group consisting of OH, halo, cyano, nitro, $N(R^{3a})R^{3b}$, C_{1-4} alkyl and C_{1-4} alkoxy; and

the compound comprises at least one ~~structural fragment of~~structure represented by formula Ib, Ic, Id, Ie or If in which R^7, R^8, R^9, R^{10} or R^{11}, respectively, represents branched, cyclic or part cyclic C_{3-5} alkyl.

67. (Previously Presented) A compound as claimed in Claim 65, wherein aryl is phenyl or naphthyl.

68. (Currently Amended) A compound as claimed in Claim 65, wherein alkyl and alkoxy groups are~~, where appropriate~~:

(a) straight-chain;

(b) branched-chain and/or cyclic; or

(c) part cyclic/acyclic.

69. (Currently Amended) A compound as claimed in Claim 65, wherein alkyl and alkoxy groups are~~, where appropriate~~:

(a) saturated or unsaturated;

(b) interrupted by one or more oxygen and/or sulfur atoms; and/or

(c) unless otherwise specified, substituted by one or more halo atoms.

70. (Currently Amended) A compound as claimed in Claim 65, which is a compound of formula II,



II

wherein

R^1 represents Het^1, $R^{1a}C(O)$- or D-A-N(H)-Q^3-Q^2-Q^1-C(O)-E-C(O)-;

Q^1 is absent or represents a ~~structural fragment of~~structure represented by formula Ia, Ib, Ic, Id, Ie or If;

Q^2 represents a ~~structural fragment of~~structure represented by formula Ib, Ie or If; and

Q^3 represents a ~~structural fragment of~~structure represented by formula Ib, Id, Ie or If~~, ; and~~

~~Het^1, R^{1a}, D, A, E, R^{2a}, R^{2b}, A and the structural fragments of formulae Ia, Ib, Ic, Id, Ie and If are as defined in any one of Claims 16 to 20;~~ provided that:

(a) at least one of Q^1, Q^2 and Q^3 represents a ~~structural fragment of~~structure represented by formula Id, Ie or If; and

(b) at least one of R^6 or R^7, R^8, R^9, R^{10} and R^{11} ~~(whichever is/are present)~~ represents branched, cyclic or part cyclic C_{3-5} alkyl, or a pharmaceutically acceptable derivative thereof.

71. (Currently Amended) A compound as claimed in Claim 65, wherein the compound comprises:

(a) at least one ~~structural fragment of~~structure represented by formula Ib in which G represents N and R^6 represents branched, cyclic or part cyclic C_{3-5} alkyl;

(b) at least one ~~structural fragment of~~structure represented by formula Id in which p represents 0 and R^9 represents branched, cyclic or part cyclic C_{3-5} alkyl; and/or

(c) at least one ~~structural fragment of~~structure represented by formula Ie in which q represents 0 and R^{10} represents branched, cyclic or part cyclic C_{3-5} alkyl.

72. (Withdrawn) A compound as claimed in Claim 65, wherein each of the at least one branched, cyclic or part cyclic C_{3-5} alkyl groups independently represents isopropyl, cyclopropylmethyl, isopentyl or cyclopentyl.

73. (Currently Amended) A compound as claimed in Claim 65, wherein the compound comprises at least one ~~structural fragment of~~structure represented by formula Ib, Ic, Id, Ie or If in which R^7, R^8, R^9, R^{10} or R^{11}, respectively, represents isopropyl.

74. (Currently Amended) A compound as claimed in Claim 65, which compound comprises at least one ~~structural fragment of~~structure represented by the formula



75-94. (Canceled)

95. (Currently Amended) A compound of formula IIa,



IIa

[[



IIa

]]

wherein

R^1 represents

a~~A~~ nine-membered aromatic heterocycle containing two heteroatoms selected from N, O and S,

$R^{1a}C(O)$- or

D-A-N(H)-Q^3-Q^2-Q^1-C(O)-E-C(O)-;

R^{1a} represents

H,

p~~P~~henyl ~~(which latter group is~~ optionally substituted by C_{1-2} alkyoxy~~)~~,

9,10-dioxo-9,10-dihydroanthracenyl ~~(which latter group is~~ optionally substituted by C_{1-2} alkoxy~~)~~,

saturated, optionally branched C_{1-6} alkyl or

saturated C_{1-3} *n*-alkyl, ~~which latter group is~~ terminated by phenyl ~~(which latter group is~~ optionally substituted by C_{1-2} alkoxy~~)~~;

A represents saturated C_{2-4} alkylene or $(CH_2)_{1-3}$-C(O)N(H)-$(CH_2)_{2-4}$;

D represents $-N(R^{2a})R^{2b}$;

R^{2a} and R^{2b} independently represent

C_{1-3} alkyl or a nine- or ten-membered aromatic heterocycle containing one to three heteroatoms selected from N, O and S, or

R^{2a} and R^{2b} together represent $(CH_2)_{3-5}$~~, which alkylene group is~~ optionally interrupted by NR^4;

R^4 represents

C_{1-3} alkyl or a nine~~non~~- or ten~~tem~~-membered aromatic heterocycle~~heterocyle~~ containing one to three heteroatoms selected from N, O and S;

E represents

-(2,5-indolyl)-,

-$(CH_2)_{0-2}$-(2,6-indolyl)-,

-CH=CH-(2,6-indolyl)-,

trans-ethenylene,

trans-cyclopropylene,

1,3- or 1-4-phenylene,

-CH_2N(H)C(O)-(1,3- or 1,4-phenylene)-C(O)N(H)CH_2-,

or one of the following structures~~structural fragments~~



Q^1 is absent or represents a ~~structural fragment of~~structure represented by formula Ia, Ib, Ic, Id, Ie or If;

Q^2 represents a ~~structural fragment of~~structure represented by formula Ib, Ie or If;

Q^3 represents a ~~structural fragment of~~structure represented by formula Ib, Id, Ie or If;

wherein the structures~~structural fragments~~ of formulae Ia, Ib, Ic, Id, Ie and If are as follows



Ia



Ib



Ic



Id



Ie



If

wherein

R^6 represents H or, when G represents N, R^6 ~~may also~~ represents H or branched, cyclic or part cyclic C_{3-5} alkyl;

R^7, R^8, R^9, R^{10} and R^{11} independently represent saturated, optionally branched C_{1-6} alkyl or R^8 represents H;

provided that the compound comprises at least ~~on structural fragment of~~one structure represented by formula Ie in which R^{10} represents branched, cyclic or part cyclic C_{3-5} alkyl.

96. (Currently Amended) A compound as claimed in Claim 95 wherein the compound comprises at least one ~~structural fragment of~~structure represented by formula Ie in which R^{10} represents cyclopropylmethyl, isopentyl, cyclopentyl or isopropyl.

97. (Currently Amended) A compound as claimed in Claim 95 wherein the compound comprises at least one ~~structural fragment of~~structure represented by formula Ie in which R^{10} represents isopropyl.

98. (Currently Amended) A compound of formula IIb,



IIb

[[



IIb

]]

wherein

R^1 represents

a nine-membered aromatic heterocycle containing two heteroatoms selected from N, O and S,

HC(O)-,

(methoxyphenyl)C(O)-,

(9,10-dioxo-9,10-dihydroanthracenyl)C(O)-,

(saturated C_{1-3} alkyl) C(O)-,

(methoxyphenylacetyl)C(O)-, or

$(CH_3)_2N$-A-N(H)-Q^3-Q^2-Q^1-C(O)-E-C(O)-;

A represents saturated C_{2-4} *n*-alkylene or $(CH_2)_2$-C(O)N(H)-$(CH_2)_3$;

E represents $-CH_2N(H)C(O)$-(1,3-phenylene)-C(O)N(H)CH_2-;

Q^1 is absent or represents a ~~structural fragment of~~structure represented by formula Ia, Ib, Ic, Id, Ie or If;

Q^2 represents a ~~structural fragment of~~structure represented by formula Ib, Ie or If;

Q^3 represents a ~~structural fragment of~~structure represented by formula Ib, Id, Ie or If;

wherein the structures~~structural fragments~~ of formulae Ia, Ib, Ic, Id, Ie and If are as follows



Ia



Ib



Ic



Id



Ie



If

wherein

R^6 represents H or, when G represents N, R^6 ~~may also~~ represents H or branched, cyclic or part cyclic C_{3-5} alkyl;

R^7, R^9, R^{10} and R^{11} independently represent saturated, optionally branched C_{1-3} alkyl;

provided that the compound comprises at least one ~~structural fragment of~~structure represented by formula Ie in which R^{10} represents branched, cyclic or part cyclic C_{3-5} alkyl.

99. (Currently Amended) A compound as claimed in Claim 98, wherein the compound comprises at least one ~~structural fragment~~

~~of~~structure represented by formula Ie in which R^{10} represents cyclopropylmethyl, isopentyl, cyclopentyl or isopropyl.

100. (Currently Amended) A compound as claimed in Claim 98, wherein the compound comprises at least one ~~structural fragment of~~structure represented by formula Ie in which R^{10} represents isopropyl.

101. (Previously Presented) A compound as claimed in Claim 65, which compound is selected from the following:

(i) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1-*H*-pyrrol-3-yl]-4-[(3,3-dimethylbutanoyl)amino]-1-methyl-1*H*-pyrrole-2-carboxamide;

(ii) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(iii) *N*-[3-(Dimethylamino)propyl]-2-({[4-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;

(iv) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]-4-({[4-(formylamino)-1-isopropyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-1-isopropyl-1*H*-pyrrole-2-carboxamide

(v) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(formyl-amino)-1-isopentyl-1*H*-pyrrole-2-carboxamide;

(vi) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-4-(formyl-amino)-1-isopropyl-1*H*-pyrrole-2-carboxamide;

(vii) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-2-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;

(viii) 4-({[4-(Formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-1-iso-propyl-*N*-[1-methyl-5-({[3-(4-morpholinyl)propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1*H*-pyrrole-2-carboxamide;

(ix) 4-(Formylamino)-*N*-[1-isopropyl-5-({[1-methyl-5-({[3-(1-pyrrolidinyl)-propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(x) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xi) 2-(Acetylamino)-*N*-[5-({[5-({[3-(dimethylamino)propyl]amino}-carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide;

(xii) 2-(Acetylamino)-*N*-[5-({[4-({[3-(dimethylamino)propyl]amino}-carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-5-isopropyl-1,3-thiazole-4-carboxamide;

(xiii) 2-(Acetylamino)-*N*-(5-{[(3-{[3-(dimethylamino)propyl]amino}-3-oxo-propyl)amino]carbonyl}-1-methyl-1*H*-pyrrol-3-yl)-5-isopropyl-1,3-thiazole-4-carboxamide;

(xiv) N^1,N^3-Bis(2-{[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-amino}-2-oxoethyl)isophthalamide;

(xv) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]-4-(acetylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xvi) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(acetyl-amino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xvii) N^2,N^5-Bis[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xviii) N^2,N^5-Bis[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]-amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xix) N^2,N^5-Bis[5-({[5-({[3-(dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xx) N^2,N^5-Bis[1-isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl)-propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(xxi) 2-({[4-({[4-(Acetylamino)-1-methyl-1*H*-imidazol-2-yl]carbonyl}-amino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-*N*-[3-(dimethylamino)-propyl]-5-isopropyl-1,3-thiazole-4-carboxamide;

(xxii) 4-(Acetylamino)-*N*-[1-isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl) propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxiii) *N*-[1-Isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl)-propyl]amino}carbonyl)-1*H*-pyrrol-3-

yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxiv) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-4-({[5-(formylamino)-2-methyl-3-thienyl]carbonyl}amino)-1-isopentyl-1*H*-pyrrole-2-carboxamide;

(xxv) *N*-[5-({[5-({[3-(dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-5-isopropyl-2-[(3-methoxybenzoyl)amino]-1,3-thiazole-4-carboxamide;

(xxvi) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-4-{[(5-{[(9,10-dioxo-9,10-dihydro-2-anthracenyl)carbonyl]-amino}-2-methyl-3-thienyl)carbonyl]amino}-1-isopentyl-1*H*-pyrrole-2-carboxamide;

(xxvii) *N*-[1-(Cyclopropylmethyl)-5-({[5-({[3-(dimethylamino)propyl]-amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxviii) 1-Cyclopentyl-*N*-[5-({[3-(dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-4-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]-carbonyl}-amino)-1*H*-pyrrole-2-carboxamide;

(xxix) N^2,N^7-Bis[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthrenedicarboxamide;

(xxx) 4-(Formylamino)-*N*-[1-isopentyl-5-({[1-methyl-5-({[3-(4-methyl-1-piperazinyl)propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxxi) 4-(Acetylamino)-*N*-[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxxii) 4-(Formylamino)-*N*-[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1-methyl-1*H*-pyrrole-2-carboxamide;

(xxxiii) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-[(3-methoxybenzoyl)amino]-1-methyl-1*H*-pyrrole-2-carboxamide; and

(xxxiv) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-{[(4-methoxyphenyl)acetyl] amino}-1-methyl-1*H*-pyrrole-2-carboxamide.

102. (Previously Presented) A compound as claimed in Claim 101 which is:

(a) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopropyl-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(b) *N*-[3-(Dimethylamino)propyl]-2-({[4-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;

(c) *N*-[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-2-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-5-isopropyl-1,3-thiazole-4-carboxamide;

(d) *N*-[5-({[5-({[3-(Dimethylamino)propyl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1-isopentyl-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide;

(e) N^2,N^5-Bis[1-isopentyl-5-({[1-methyl-5-({[3-(4-morpholinyl)propyl]-amino}carbonyl)-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-1*H*-indole-2,5-dicarboxamide;

(f) *N*-[1-(Cyclopropylmethyl)-5-({[5-({[3-(dimethylamino)propyl]-amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]amino}carbonyl)-1*H*-pyrrol-3-yl]-4-(formylamino)-1-methyl-1*H*-pyrrole-2-carboxamide; or

(g) N^2,N^7-Bis[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1*H*-pyrrol-3-yl]-9,10-dihydro-2,7-phenanthrenedicarboxamide.

103. (Withdrawn) A compound as claimed in Claim 95 which is *N*-[3-(dimethylamino)-propyl]-2-({[4-({[4-(formylamino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}-amino)-1-methyl-1*H*-pyrrol-2-yl]carbonyl}amino)-5-isopropyl-1,3-thiazole-4-carboxamide.

104. (Previously Presented) A compound as claimed in Claim 65, which binds to and/or has specificity for DNA sequences that contain at least one GC base pairing.

105. (Currently Amended) A compound as claimed in Claim 95 or 98, which binds to and/or has specificity for DNA sequences that contain at least one GC base pairing, ~~104, which is:~~

~~(i) a compound of formula I, as defined in any one of Claims 95-97~~ provided that the compound comprises at least one ~~structural fragment of~~structure represented by formula Id, Ie or If~~; or~~

~~(ii) a compound of formula II, as defined in any one of Claims 98-101~~.

106. (Previously Presented) A compound as claimed in Claim 65 which has different binding affinities at different

minor groove binding sites in double-stranded DNA molecules having more than one minor groove binding site.

107. (Previously Presented) A compound as claimed in Claim 106, wherein the different minor groove binding sites comprise solely AT base pairs.

108. (Previously Presented) A pharmaceutical formulation including a compound as defined in Claim 65 in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

109. (Withdrawn) A method of treatment of a disease that relies upon DNA replication for its propagation, which method comprises administration of a therapeutically effective amount of a compound as defined in Claim 65 to a person suffering from that disease.

110. (Withdrawn) A method of treatment of cancer, which method comprises administrations of a therapeutically effective amount of a compound as defined in Claim 65 to a person suffering from cancer.

111. (Currently Amended) A method of treatment of a viral, bacterial, fungal or other microbial infection, which method comprises administration of a therapeutically effective amount of a compound as~~ad~~ defined in Claim 65 to a person suffering from such an infection.

112. (Currently Amended) A method of treating a viral, bacterial, fungal or other microbial ~~(e.g. parasitic)~~ infection, where the viral, bacterial, fungal or other microbial ~~(e.g. parasitic)~~ infective agent is resistant to one or more anti-viral, anti-bacterial, anti-fungal or other anti-microbial ~~(e.g. anti parasitic)~~ agents, respectively, that do not act by inhibiting DNA replication, which method comprises administration

of a therapeutically effective amount of a compound as defined in Claim 65 to a person having the~~that~~ infection.

113. (Withdrawn) A method of treatment of a disease that relies upon DNA replication for its propagation, which method comprises administration, to a person suffering from that disease, of a therapeutically effective amount of a compound as defined in Claim 65 in combination with one or more other agents that are known to be effective in treating that disease.

114. (Withdrawn) A combination product comprising components:

(A) a formulation comprising a compound as defined in Claim 65; and

(B) a formulation comprising one or more other chemical agents that are known to be effective in treating diseases that rely upon DNA replication for their propagation.

115. (Withdrawn) A combination product as claimed in Claim 114, wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

116. (Withdrawn) A combination product as claimed in Claim 114, wherein (A) and (B) are presented as separate components.

117. (Withdrawn) A combination product as claimed in Claim 114, wherein (A) and (B) are presented as a single formulation.

118. (Withdrawn) A method of inhibiting DNA replication, which method comprises contacting the DNA with an inhibitory amount of a compound as defined in Claim 65.

119. (Withdrawn) A method of stabilising a DNA duplex formed between first and second single strands of DNA, which

method comprises contacting that DNA duplex with a compound as defined in Claim 65.

120. (Withdrawn) A method of enhancing the difference in melting temperatures between first and second DNA duplexes, wherein each DNA duplex is formed from a first single strand of DNA that is the same in each duplex and a second single strand of DNA that is different in each duplex, which method comprises contacting each DNA duplex with a compound as defined in Claim 65.

121. (Currently Amended) A process for the preparation of compounds of formula I as defined in Claim 65 which comprises:

(a) reaction of a compound of formula III,



III

wherein A^a represents A or, when a represents 0, then A^a ~~may also~~ represents A or A^2, ~~and Q, D, A and A^2 are as defined in Claim 16~~ ~~and~~ a is as defined below, with a compound of formula IV,



IV

wherein A^b represents a direct bond or $-A^1-C(O)-$, ~~as appropriate,~~ L^1 represents a leaving group, a and b both represent integers from 0 to 5, the sum of a and b~~the two~~ being 2, 3, 4 or 5~~, and R^1 and Q are as defined in Claim 65~~;

(b) for compounds of formula I in which R^1 represents D-A-N(H)-$[Q]_n$-C(O)-E-C(O)-, reaction of two equivalents of a compound of formula V,



V

~~wherein Q, n, A and D are as defined in Claim 65,~~ with a compound of formula VI,

$$L^2\text{-}C(O)\text{-}E\text{-}C(O)\text{-}L^2 \quad \text{VI}$$

wherein L^2 represents a leaving group, the two L^2 groups being the same or different~~, and E is as defined in Claim 65~~; or

(c) deprotection of a protected derivative of a compound of formula I ~~as defined in Claim 65~~.

122. (Withdrawn) A compound of formula V, as defined in Claim 121, or a protected derivative thereof.